Edwards Lifesciences

$184.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$12.23 (+7.08%) Today
$0.00 (0.00%) As of 4:11 AM EDT after-hours

Why Robinhood?

You can buy or sell EW and other stocks, options, ETFs, and crypto commission-free!

About EW

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. Read More The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Employees
13,900
Headquarters
Irvine, California
Founded
1958
Market Cap
38.33B
Price-Earnings Ratio
34.99
Dividend Yield
Average Volume
2.31M
High Today
$185.32
Low Today
$170.99
Open Price
$170.99
Volume
1.51M
52 Week High
$247.64
52 Week Low
$154.52

Collections

EW News

ReutersMar 29

BRIEF-Edwards Lifesciences Says Sapien 3 Valve Shows "Excellent" Results At 2 Years

March 29 (Reuters) - Edwards Lifesciences Corp: * EDWARDS SAPIEN 3 VALVE SHOWS EXCELLENT RESULTS AT 2 YEARS * EDWARDS LIFESCIENCES CORP SAYS DEATH AND STROKE
14
ReutersMar 28

BRIEF-Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On Covid-19

March 28 (Reuters) - Edwards Lifesciences Corp: * EDWARDS PAUSES ENROLLMENTS IN PIVOTAL MITRAL, TRICUSPID TRIALS IN RESPONSE TO HOSPITALS’ FOCUS ON COVID-19 *
79

EW Earnings

$0.00
$0.49
$0.99
$1.48
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
per share
Actual
Expected Apr 21, After Hours

People Also Bought

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.